1,720,967 research outputs found
Prion-like doppel gene (PRND): a new molecular marker potentially involved in leukemogenesis
No full textPrion-like doppel gene (PRND): a new molecular marker potentially involved in leukemogenesis
No full textIl gene della proteina simil-prionica doppel (Dpl): un nuovo marker molecolare potenzialmente coinvolto nella leucemogenesi.
No full textAberrant expression of the prion-like protein doppel in blast cells of acute myeloid leukemias and myelodisplastic syndromes
No full textExpression of the prion-like protein doppel in blast cells of acute myeloid leukemias and myelodisplastic syndromes: comparison with normal bone marrow cells
No full textTestina celtica in bronzo da Casteggio
No full textA Celtic bronze bearded head of Casteggio.
A rare bronze bearded head found during a recent excavation of ancient Clastidium is presented in this article. The closest stylistic similarity make one suppose that it belonged to an anthropomorphic sword handle dated between the end of the second-beginning of the first century B.C.Petite tête celtique en bronze de Casteggio.
Dans cet article, on présente une rare petite tête en bonze retrouvée dans des fouilles récentes dans l’emplacement de l’ancien Clastidium. L’objet, qui est comparable aux poignées anthropomorphes des épées laténiennes, est sûrement un produit d’importation et il est datable, pour des raisons stylistiques, entre la fin du IIe et le début du Ier siècle avant
J.-C.Invernizzi Rosanina. Testina celtica in bronzo da Casteggio. In: Etudes Celtiques, vol. 31, 1995. pp. 67-75
Thalidomide plus intermediate-dose dexametasone is an effective but toxic treatment for patients with AL (primary) amyloydosis
No full textBased on the efficacy of thalidomide in multiple myeloma and on its synergy with dexamethasone on myeloma plasma cells, we evaluated the combination of thalidomide (100 mg/d, with 100-mg increments every 2 weeks, up to 400 mg) and dexamethasone (20 mg on days 1-4) every 21 days in 31 patients with primary amyloidosis (AL) whose disease was refractory to or had relapsed after first-line therapy. Eleven (35%) patients tolerated the 400 mg/d thalidomide dose. Overall, 15 (48%) patients achieved hematologic response, with 6 (19%) complete remissions and 8 (26%) organ responses. Median time to response was 3.6 months (range, 2.5-8.0 months). Treatment-related toxicity was frequent (65%), and symptomatic bradycardia was a common (26%) adverse reaction. The combination of thalidomide and dexamethasone is rapidly effective and may represent a valuable second-line treatment for AL
- …
